Drug design, development and therapy, 2018, Vol.12, p.3563-3571
2018
Details
- Autor(en) / Beteiligte
- Titel
- Lobaplatin inhibits breast cancer progression, cell proliferation while it induces cell apoptosis by downregulating MTDH expression
- Ist Teil von
- Drug design, development and therapy, 2018, Vol.12, p.3563-3571
- Ort / Verlag
- New Zealand: Dove Medical Press Limited
- Erscheinungsjahr
- 2018
- Link zum Volltext
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Lobaplatin shows antitumor activity against a wide range of tumors, including metastatic breast cancer (BCa). The overexpression of metadherin (MTDH) is associated with poor prognosis of BCa patients. This study was designed to investigate the effect of lobaplatin on MCF-7 cell proliferation and its association with MTDH expression. Clinical treatment for BCa using lobaplatin, in combination with other general chemotherapy drugs, was administered to 32 BCa patients. The safety, effectiveness, and prognosis in lobaplatin-treated BCa patients were compared with those in controls (n=32). In vitro experiments were performed in MCF-7 cells to investigate the effect of lobaplatin on cell proliferation, apoptosis, and MTDH expression. We found the intraoperative local chemotherapy using lobaplatin was safe and effective for BCa treatment, in comparison with the patients administered general chemotherapy drugs. Treatment of MCF-7 cell cultures with lobaplatin significantly reduced cell proliferation and increased cell apoptotic percentage. The expression of MTDH and Bcl-2 was inhibited by lobaplatin and that of Bax was increased by lobaplatin. Moreover, we observed the inhibition of MTDH by shRNA reduced cell proliferation and enhanced cell apoptosis. Lobaplatin was a safe and effective adjuvant chemotherapy for BCa. The effect of lobaplatin on inhibiting MCF-7 cell proliferation and inducing cell apoptosis might be, as least in part, mediated by suppressing the expression of oncogene MTDH.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1177-8881eISSN: 1177-8881DOI: 10.2147/DDDT.S163157Titel-ID: cdi_doaj_primary_oai_doaj_org_article_c4ffea33e612454599ea8bdecfcdf237
- Format
- –
- Schlagworte
- Adjuvant chemotherapy, Adjuvant treatment, Anticancer properties, Antineoplastic Agents - pharmacology, Antitumor activity, Apoptosis, Apoptosis - drug effects, Bcl-2 protein, Breast cancer, Breast Neoplasms - drug therapy, Breast Neoplasms - metabolism, Breast Neoplasms - pathology, Cancer, Cancer metastasis, Cancer therapies, Cancer treatment, Carboplatin, Care and treatment, Cell Adhesion Molecules - biosynthesis, Cell Adhesion Molecules - deficiency, Cell Adhesion Molecules - genetics, Cell Adhesion Molecules - metabolism, Cell cycle, Cell growth, Cell proliferation, Cell Proliferation - drug effects, Chemotherapy, Comparative analysis, Cyclobutanes - pharmacology, Development and progression, Down-Regulation - drug effects, Drugs, Esophagus, Female, Flow Cytometry, Gastric cancer, Gene Expression Profiling, Gene Expression Regulation, Neoplastic - drug effects, Humans, Lobaplatin, Lung cancer, MCF-7 Cells, Medical research, Medicine, Experimental, Membrane Proteins, Metadherin, Metastases, Metastasis, MicroRNAs, Middle Aged, Organoplatinum Compounds - pharmacology, Original Research, Patients, Prognosis, Proliferation, Prostate cancer, Real-Time Polymerase Chain Reaction, RNA-Binding Proteins, Surgery, Tumor Cells, Cultured, Tumors